In clinical practice, Rituximab is primarily used to mitigate RA symptoms by suppressing B cell function, particularly when TNF inhibitors fail, with therapeutic outcomes varying based on the m6A modification profile [242]. This evidence concerns the gene TNF and rheumatoid arthritis.